Antibody Drug Conjugates (ADCs) have been a game-changer in precision oncology over the past 25 years. Originally a bold concept, ADCs have now become a cornerstone in treating both blood cancers and solid tumors. The latest generation of ADCs features advanced technologies like smarter linkers, novel payloads, and higher drug-antibody ratios, pushing the boundaries of […]
Tag: adcs
Analysts’ Insights on BioNTech’s Future
BioNTech, a Germany-based biotech company, is at the forefront of developing cancer therapeutics and vaccines for infectious diseases, including COVID. With a diverse oncology pipeline that includes mRNA-based drugs, cell therapies, bispecific antibodies, and ADCs, BioNTech has established partnerships with major pharmaceutical companies like Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Its COVID vaccine, Comirnaty, […]
ADCs Impact on NSCLC Market Growth
Antibody drug conjugates (ADCs) are projected to dominate the $3.9 billion NSCLC market by 2032. Despite a historical lack of ADC presence in NSCLC, recent approvals like AstraZeneca and Daiichi Sankyo’s Enhertu signify a turning point in targeting HER2-mutated tumors. Read more about this — thepharmaletter.com
